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INTRODUCTION
High-dose chemotherapy with hematopoietic support is
an effective therapy for many malignancies, including
Hodgkin’s disease, non-Hodgkin’s lymphoma, and acute
myeloid leukemia and is gaining wide acceptance in the
treatment of breast cancer. Over the past decade, autologous
bone marrow transplantation (ABMT) has allowed the use
of high-dose chemotherapy regimens in patients with
metastatic breast cancer or high-risk primary breast cancer
[1,2]. Nonrandomized uncontrolled studies using such regi-
mens have found improvements in response rate, median
survival, and disease-free survival [1,3]. However, high-dose
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ABSTRACT
This study assessed the safety and efficacy of recombinant human interleukin (rhIL)-11 in decreasing platelet trans-
fusion requirements in patients with breast cancer who were undergoing autologous bone marrow transplantation
(ABMT) with peripheral blood progenitor cell (PBPC) support. After high-dose therapy with cyclophosphamide,
cisplatin, and carmustine, 80 patients were randomized to one of three treatment groups: placebo (26), 25 µg/kg of
rhIL-11 (28), and 50 µg/kg of rhIL-11 (26). Of those randomized, 75 (94%) received at least one dose of the masked
study drug and the remaining 5 (6%) withdrew consent before study drug administration. In the placebo group,
each patient received an average 12.4 (10.2) platelet transfusions vs. 9.2 (5.0) in the 25-g/kg rhIL-11 group ( p
 0.17) and 9.9 (3.5) in the 50-g/kg rhIL-11 group ( p  0.34). There was no statistically significant difference
between the rhIL-11 groups and the placebo group in the median number of days to platelet recovery. Neutrophil
and red blood cell recovery were similar for all treatment groups. The imbalance in the number of patients already
alloimmunized at study entry in the rhIL-11 groups (12) and in the placebo group (1) may have confounded the pri-
mary efficacy assessment. Most adverse events were related to the high-dose chemotherapy. Generally mild edema
and minor conjunctival bleeding (grades 1 or 2) were statistically associated with rhIL-11 administration (p  0.04).
There was no association between rhIL-11 and the occurrence of atrial arrhythmias, although there was a sugges-
tion of an association with rhIL-11, 5 of 50 cases vs. 1 of 25 in the placebo group. Two cardiovascular events, tachy-
cardia and hypotension (grade 1 or 2), occurred in the 50-g/kg rhIL-11 group. The number of patients who dis-
continued study drug dosing because of an adverse event was distributed across all treatment groups. In summary,
rhIL-11 was safe and well tolerated in this study. The results did not demonstrate that rhIL-11 treatment signifi-
cantly decreased platelet transfusion requirements after high-dose chemotherapy with ABMT and PBPC support.
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chemotherapy regimens, particularly with alkylating agents,
often cause severe thrombocytopenia. Typically, patients
undergoing ABMT need platelet transfusions for periods of
weeks to, occasionally, months.
In recent studies, ABMT has been supplemented by the
administration of autologous peripheral blood progenitor
cells (PBPC), collected by cytapheresis following “mobiliza-
tion” with chemotherapeutic agents or hematopoietic
growth factors such as granulocyte colony-stimulating factor
(G-CSF). This regimen has shortened the period of platelet
transfusion dependence resulting from the high-dose
chemotherapy, with the result that patients can be dis-
charged earlier. At Duke University, patients treated with
cyclophosphamide, cisplatin, and carmustine (BCNU) fol-
lowed by ABMT and PBPC infusions required an average of
9.6 transfusions [4].
Platelet transfusions are costly and associated with risks
of alloimmunization, transmission of infectious disease, and
transfusion reactions. Therefore, we investigated a novel
thrombopoietic factor, recombinant interleukin (rhIL-)11
(Neumega, Genetics Institute, Cambridge, MA) [5], which
has been shown to stimulate both murine and human
megakaryocytopoiesis [6–8], increase platelet production in
a variety of animal species, and accelerate the recovery of
platelet counts following myelosuppressive chemotherapy
in mice [9]. These results from animal studies were borne
out in clinical trials. In a dose-escalating study, rhIL-11 (10,
25, 50, and 75 g/kg once daily) was administered subcuta-
neously (SC) for up to 28 days to patients with high-risk
breast cancer, who were undergoing ABMT and intensive
myelosuppressive chemotherapy [10]. On average, patients
required fewer platelet transfusions and had earlier platelet
recovery with increasing doses of rhIL-11.
This report describes the results of a phase II study of
rhIL-11 (25 and 50 g/kg) vs. placebo, which was undertak-
en to learn whether rhIL-11 would decrease the use of
platelet transfusions and accelerate platelet recovery in
patients with breast cancer who were undergoing high-dose
chemotherapy with ABMT and PBPC support.
MATERIALS AND METHODS
Selection of patients
Women with pathologically confirmed breast cancer
(stage II or IIIA with 4 positive nodes or stage IIIB or IV)
were eligible to participate in the study if they were at least 18
years old; had an Eastern Cooperative Oncology Group
(ECOG) performance status of 0 or 1; had normal respiratory,
cardiac, hepatic, and renal function; and had no child-bearing
potential or were practicing a medically approved method of
contraception at the time of study entry and continued to do
so for the duration of the study. All patients were required to
give written informed consent, and the protocol was approved
by the Institutional Review Board of the Duke University
Medical Center. The patients received three or four cycles of
doxorubicin-based induction chemotherapy followed by high-
dose chemotherapy and hematopoietic support.
Patients were excluded if they had a history of metastat-
ic disease in the central nervous system, deep-vein thrombo-
sis, pulmonary embolus, stroke, transient ischemic attacks or
other thromboembolic disease within the past 6 months, or
atrial ﬁbrillation or conditions known to predispose to atrial
fibrillation. Patients who had undergone bone marrow or
peripheral stem cell harvest purged with monoclonal anti-
bodies or chemotherapy in vitro, had experienced clinically
evident hemolytic anemia or significant bleeding, or had
used aspirin or nonsteroidal anti-inﬂammatory agents with-
in 1 week before study entry also were not allowed to enter
the study. In addition, patients with known hypersensitivity
to any Escherichia coli protein who were seropositive for
human immunodeﬁciency virus and who were pregnant or
breast feeding were excluded.
Study medication
Recombinant human interleukin 11 (Neumega rhIL-11
Growth Factor), derived from genetically altered Escherichia
coli, was provided by Genetics Institute. rhIL-11 was provid-
ed as a lyophilized powder in labeled vials. Each vial was
reconstituted with 1 mL of sterile water for injection. The
ﬁnal concentration of rhIL-11 after reconstitution was 5.0
mg/mL (pH 7.0).
Study design
This randomized double-blind study compared two doses
of rhIL-11 (25 or 50 g/kg) vs. placebo in women with breast
cancer who were undergoing high-dose chemotherapy with
autologous bone marrow transplantation and PBPC support
(Fig. 1). Patients were randomized to one of three treatment
groups: rhIL-11 25 g/kg SC once daily, rhIL-11 50 g/kg
SC once daily, or placebo. Because the volumes of the lower
and higher doses of rhIL-11 were different, patients who
were assigned to the placebo group received either a lower
Figure 1. Study design
Patients with high-risk primary breast cancer or chemotherapy-responsive
metastatic breast cancer received high-dose cyclophosphamide, cisplatin, and
BCNU followed by autologous bone marrow and peripheral blood progenitor
cell support and were subsequently randomized to rhIL-11 25 µg/kg/day, 50
µg/kg/day, or placebo for 7–21 days after transplantation.
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(0.005 mL/kg) or higher (0.01 mL/kg) volume of placebo.
This procedure ensured that masking was maintained. rhIL-
11 was administered as a daily SC injection for 7–21 days,
according to the criteria below (platelet count 20,000 for
two consecutive days independent of transfusion). Patients
received preparative chemotherapy, which consisted of
cyclophosphamide (1875 mg/M2/day intravenously [IV] over
1 hour) and cisplatin (55 mg/M2/day IV as a continuous infu-
sion), each administered on the ﬁfth, fourth, and third days
before study drug administration (days 6, 5, and 4), and
carmustine (600 mg/M2 at a rate of 5 mg/M2/minute), admin-
istered on the second day before study drug administration
(day 3). The rh-IL11 was begun on day 1, the ﬁrst day of
PBPC infusion, and continued until the platelet count was
20,000 for 2 consecutive days, independent of transfusions.
Platelet counts were monitored daily. To minimize the
risk of hemorrhagic myocarditis due to platelet dysfunction
caused by high-dose chemotherapy [4], two bags of single-
donor platelets (i.e., two platelet transfusions) were given to
each patient the day before the first reinfusion and study
drug administration (day 2), regardless of the patient’s
platelet count. In patients not refractory to platelet transfu-
sions, during the ﬁrst 12 days after completion of hemato-
poietic stem cell infusions, platelets were transfused for a
platelet count of 25,000 cells/µL. Subsequently, platelets
were transfused if the count was 15,000 cells/L. For
counts between 15,000 and 25,000 cells/L after day 12,
patients were transfused only if the absolute neutrophil
count (ANC) was 500 cells/L. All platelet transfusions
were single-donor pheresed platelets. Patients refractory to
platelet transfusions (i.e., with posttransfusion increases in
platelet counts under 5000 L) were transfused only if their
platelet counts dropped below 5000 L at any time. Every
platelet transfusion was followed by a 1-hour posttransfu-
sion platelet count. Patients had a human leukocyte antigen
(HLA) cytotoxic antibody panel, and patients with 15 of
30 positive wells were considered alloimmunized. Patients
who were alloimmunized and had a post-platelet transfusion
increment of 5000 L received HLA-matched platelets.
Patients were diuresed to maintain their baseline
weight. If a patient’s serum potassium concentration was
4.0 mEq/L, the patient was given potassium supplements
with the goal of maintaining a serum potassium concentra-
tion 4.0 mEq/dL.
All patients received a standard prophylactic antibiotic
regimen consisting of ciproﬂoxacin 500 mg by mouth every 8
hours and rifampin 300 mg by mouth every 12 hours, begin-
ning on day 2. Febrile neutropenia and other infections were
treated according to standard practice at Duke University.
Safety was assessed on the basis of the number of
patients reported to be experiencing adverse events, the
severity of adverse events, the time course of ANC recovery,
red blood cell (RBC) transfusions, changes in laboratory test
results, and the number of patients with tumor progression.
In addition, Holter monitoring was performed before the
ﬁrst PBPC reinfusion/study drug dose and continued for 72
hours. Subsequently, 24-hour Holter monitoring was per-
formed again on days 8 and 16.
Before entry into the study, patients had a complete
medical history, physical examination, and laboratory evalu-
ations, including complete blood counts, serum chemistry
tests, coagulation studies, urinalysis, chest X ray, and electro-
cardiogram. A follow-up physical examination was carried
out 6 weeks after ABMT.
Blood specimens to measure platelet reticulocytes were
drawn daily, beginning on day 2. Platelet reticulocyte
counts were determined by flow cytometric analysis after
staining with thiazole orange (Reticcount, Becton Dickinson
Immunocytometry Systems, Mountainview, CA), as previ-
ously described [11]. Brieﬂy, patient blood samples were col-
lected into edetic acid anticoagulant, and platelet-rich plas-
ma (PRP) was prepared by centrifugation. An aliquot of
PRP was fixed with 1% paraformaldehyde, then a sub-
aliquot was incubated with the thiazole orange reagent for
30 minutes in the dark. Patient samples were analyzed on a
FACScan ﬂow cytometer (Becton Dickinson, San Jose, CA)
and compared with three or four normal control samples
run with each assay. Those platelets exhibiting ﬂuorescence
greater than two standard deviations (SD) above the mean
of the normal control platelet distributions were designated
as “reticulated platelets.”
Statistical analyses
The primary end points for evaluating safety were the
incidence and severity of reported adverse events and the
laboratory test results from all patients. Because the differ-
ences between the rhIL-11 treatment groups were not clini-
cally signiﬁcant, these groups were combined and contrasted
with the placebo group using Fisher’s exact test, with p 
0.05 being the signiﬁcance threshold.
The primary efﬁcacy outcome measure for this study was
the total number of platelet transfusions required by each
patient during the transplant course. Historical information
was obtained from 90 women with breast cancer who had
undergone ABMT with PBPC support at Duke University
Medical Center. This information was used to estimate the
mean, median, and variance of this patient cohort. The aver-
age number of transfusions during hematologic recovery for
this group was 9.6, with a SD  5.6. The median number of
transfusions was 8.0, indicating a right-skewed distribution
and a range spanning from 0 to 27 transfusions. On the basis
of these historical data, 75 evaluable patients were required
to provide 80% power to detect a mean reduction of at
least ﬁve platelet transfusions with either rhIL-11 dose com-
pared with placebo, using a two-sided t-test with a signiﬁ-
cance level p  0.05. The placebo group was compared with
each of the rhIL-11 groups by Dunnett’s t-test. Because no
statistically signiﬁcant differences from placebo were detect-
ed, the rhIL-11 groups were combined and t-tests were used
to characterize differences between the rhIL-11 and placebo
groups in a descriptive fashion.
The statistical analysis was done on the 75 patients who
received the study drug and not on the 80 patients random-
ized. When the statistical analysis was done on all 80
patients, however, the intent-to-treat analysis was
unchanged from the results reported in this report.
RESULTS
Patient characteristics
A total of 80 patients were randomized over a period of
22 months. As shown in Table 1, the treatment groups were
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comparable in terms of demographic or baseline character-
istics. Distribution of cancer stage was similar among treat-
ment groups, with over 60% of patients in all three groups
having stage IIIB or metastatic disease.
Patient disposition
Of the 80 patients randomized, 75 (94%) received at
least one dose of masked study drug. Of these 75 patients,
62 (83%) completed the study (21 of 26 in the placebo
group, 22 of 28 in the 25-g/kg rhIL-11 group, and 19 of
26 in the 50-g/kg rhIL-11 group). The demographic and
baseline characteristics of the patients who withdrew were
representative of the study population as a whole.
Efficacy
As shown in Table 2, the mean number of transfusions
was 12.4 per patient in the placebo group vs. 9.2 for the 25-
g/kg rhIL-11 group and 9.9 for the 50-g/kg rhIL-11
group. Although the mean values were lower in the rhIL11-
treated groups, these results did not show a statistically
significant difference from placebo. In the placebo group,
the variability in the number of platelet transfusions was
signiﬁcantly greater than that in the rhIL-11 groups, with
SD of 10.2 for the placebo group vs. only 5.0 for the 25-
g/kg rhIL-11 group and 3.5 for the 50-g/kg rhIL-11
group ( p  0.001).
Of the 16 alloimmunized patients (i.e., with positive
HLA cytotoxic antibody test results and requiring HLA-
matched platelets for transfusions), 13 were already allo-
immunized at study entry (as evidenced by positive HLA
cytotoxic test results). Of these 13 patients, only one was
randomized to the placebo group and the remaining 12
were in the rhIL-11 groups (5 in the 25-g/kg and 7 in the
50-g/kg group). Three patients (one in the placebo group
and one in each of the rhIL-11 groups) became alloimmu-
nized during the study. As shown in Table 3, alloimmunized
patients tended to require more platelet transfusions than
did nonalloimmunized patients, despite a lower platelet
count threshold for transfusion, presumably because of
reduced survival of transfused platelets.
Of the 25 patients in the placebo group, ﬁve (20%) had
delayed platelet engraftment (no engraftment 30 days after
ABMT) vs. three of 50 (6%) in the rhIL-11 groups.
The median number of days to platelet recovery
(deﬁned as the time from the ﬁrst day of PBPC infusion to
the day of the first of three consecutive platelet counts
20,000 cells/L) was 13 days for the placebo group vs.
13.5 for the combined rhIL-11 group.
The absolute platelet reticulocyte (reticulated platelet)
count has been shown to measure indirectly the rate of
platelet production [12]. In this study, the recovery of
Table 1. Patient demographics and baseline characteristics
Placebo (%) 25 g/kg (%) 50 g/kg (%) Total (%)
Sex
Women 26 (100.0) 28 (100.0) 26 (100.0) 80 (100.0)
Age (years)
Mean 44.1 43.0 42.5 43.2
Range 31–68 30–55 35–51 30–68
Race
Caucasian 22 (84.6) 24 (85.7) 21 (80.8) 67 (83.8)
Black 4 (15.4) 2 (7.1) 5 (19.2) 11 (13.8)
Other 0 2 (7.1) 0 2 (2.5)
Staging
II 6 (23.1) 7 (25.0) 6 (23.1) 19 (23.8)
IIIA 2 (7.7) 3 (10.7) 1 (3.8) 6 (7.5)
IIIB 0 1 (3.6) 2 (7.7) 3 (3.8)
IV 18 (69.2) 17 (60.7) 17 (65.4) 52 (65.0)
Menopausal status
Premenopausal 15 (57.7) 14 (50.0) 17 (65.4) 46 (57.5)
Postmenopausal 11 (42.3) 14 (50.0) 9 (34.6) 34 (42.5)
ECOG score
0 12 (46.2) 16 (57.1) 18 (69.2) 46 (57.5)
1 14 (53.8) 12 (42.9) 8 (30.8) 34 (42.5)
A total of 80 patients were randomized. The treatment groups were comparable in terms of demographic or baseline characteristics. Distribution of cancer stage
was similar among treatment groups, with over 60% of patients in all three groups having stage IIIB or metastatic disease.
Table 2. Mean number of platelet transfusions in the 25- and 50-g/kg
rhIL-11 groups vs. placebo
Difference from placebo
Treatment n Mean (SD) 95% CI p valuea
Placebo 25 12.4 (10.2)
rhIL-11
25 g/kg 26 9.2 (5.0) 7.6 to 1.1 0.17
50 g/kg 24 9.9 (3.5) 7.0 to 1.9 0.34
aDunnett’s t-test.
SD, standard deviation; CI, conﬁdence interval.
The mean number of transfusions was 12.4 transfusions/patient in the placebo
group, vs. 9.2 for rhIL-11 25 g/kg and 9.9 for rhIL-11 50 g/kg. These
results did not show a statistically signiﬁcant difference from placebo.
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platelet reticulocytes was similar among treatment groups
(Fig. 2), and platelet reticulocytes began increasing several
days before the recovery of platelet counts and the achieve-
ment of platelet transfusion independence. This result is
consistent with observations showing that an increase in
platelet reticulocytes is predictive of imminent platelet
recovery following myelosuppressive chemotherapy and
stem cell support.
Safety
Overall, rhIL-11 was well tolerated in this population.
The incidence of adverse events was similar in the three
treatment groups (Table 4), and there were no statistically
significant (p  0.05) differences between the IL-11 and
placebo groups with grade 3 or 4 adverse events.
The most commonly recorded adverse events (neu-
tropenic fever, chills, asthenia, fever, and pain) were those
often associated with chemotherapy, and their incidences
were comparable in the placebo and rhIL-11 groups.
Table 4 presents adverse events signiﬁcantly associated
with rhIL-11 treatment. Peripheral edema (grade 1 or 2) has
been observed in other studies and is due to plasma volume
expansion related to sodium and water retention [13,14].
Conjunctival bleeding (almost all grade 1) was asymptomatic
and of no clinical consequence. Of the 15 patients in the
rhIL-11 groups with conjunctival bleeding, eight were
alloimmunized and 11 had platelet counts below 20,000
cells/L at the time of conjunctival bleeding (vs. none in the
placebo group). This result may be confounded by the
imbalance in the number of alloimmunized patients among
the treatment groups.
The incidence of fever was similar in the placebo and
rhIL-11 groups (52 and 46%, respectively). Moreover, in
patients receiving rhIL-11, fever was not usually associated
with chills, as is often found with other cytokines [15–19],
conﬁrming that, unlike some other cytokines, rhIL-11 does
not cause fever. The incidence of other adverse events com-
monly associated with cytokines, such as bone pain and
myalgia, was similar in the placebo and rhIL-11 groups.
There was no statistical association between the admin-
istration of rhIL-11 and the occurrence of atrial arrhyth-
mias, and the results of Holter monitoring did not suggest
an association between administration of rhIL-11 and atrial
arrhythmias. However, there were ﬁve of 50 patients treated
with rhIL-11 and one of 25 patients treated with placebo
who developed atrial arrythemias; a larger study is required
to determine if there is a signiﬁcant association.
One patient in the placebo group died during the study.
None of the patients treated with rhIL-11 died. The num-
ber of patients who experienced disease progression during
the study was similar for all treatment groups. 
As shown in Table 5, the 11 patients who discontinued
the study drug because of an adverse event were evenly dis-
tributed across treatment groups. Patient 050 (50 g/kg
Table 3. Effect of alloimmunization on platelet transfusions
Mean platelet transfusions 
Treatment group per patient (SD) Range
Alloimmunized patients Placebo (n2) 28.0 (26.9) 9–47
rhIL-11 (n14) 12.4 (6.2) 5–26
Overall (n16) 14.4 (10.5) 5–47
Nonalloimmunized patients Placebo (n23) 11.0 (7.5) 4–38
rhIL-11 (n36) 8.4 (2.7) 3–14
Overall (n59) 9.4 (5.2) 3–38
Alloimmunized patients tended to require more platelet transfusions than nonalloimmunized patients despite a lower platelet count threshold for transfusion.
Figure 2. Platelet reticulocytes vs. time by treatment group
The number of platelet reticulocytes (1000 cells/L) was determined by dual
staining with monoclonal antibodies to CD34 and CD41 and ﬂow cytometry
for the three treatment groups: 25 g/kg, 50 g/kg, and placebo.
Table 4. Adverse events signiﬁcantly associated with rhIL-11 (p  0.05 rel-
ative to placebo)
rhIL-11 p value
Placebo (25 and 50 g/kg) (rhIL-11 vs.
Adverse event n25 (%) n50 (%) placebo)
Edema 5 (20) 23 (46) 0.04
Tachycardia 8 (32) 27 (54) 0.02
Hypotension 1 (4) 11 (22) 0.02
Conjunctival bleeding 2 (8) 15 (30) 0.04
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rhIL-11) was withdrawn because of an adverse event (ven-
tricular pause), which occurred before the start of the study
drug but was not identified until after the patient had
already received the study drug. Review of Holter monitor-
ing data recorded the day before starting the study drug
showed episodes of type II second degree atrioventricular
block and three episodes of ventricular standstill; the longest
pause was 6.79 seconds. The patient was asymptomatic.
The median number of days to neutrophil recovery to
500 cells/L was 10 days for both treatment groups
(ranges, 9–30 for placebo and 8–30 for rhIL-11). The mean
number of units of RBCs transfused was 4.5 (4.0) for the
placebo group and 4.6 (2.2) for the rhIL-11 group. None
of the patients tested developed antibodies to rhIL-11.
DISCUSSION
Thrombocytopenia after high-dose chemotherapy and
hematopoietic progenitor cell support has become an
increasingly significant problem. The use of growth
factor–primed PBPCs has reduced the duration of neu-
tropenia from a period of a few weeks to 1 week. This has
also resulted in a decrease in the requirement of the number
of platelet units transfused. However, prolonged and severe
periods of thrombocytopenia are still frequently encoun-
tered. The availability of myeloid colony-stimulating factors
and erythropoietin have led to a further escalation in the
doses of both old and new chemotherapeutic agents. Unfor-
tunately, no hematopoietic growth factor to date has
demonstrated the ability to reduce the degree of thrombo-
cytopenia. Although effective therapy, platelet transfusions
are inconvenient, expensive, potentially toxic, and associated
with the risk of development of alloimmunization [20] and
transmission of infectious diseases.
In two randomized placebo-controlled trials of rhIL-11 in
patients with chemotherapy-induced thrombocytopenia, rhIL-
11 treatment (50 g/kg SC once daily) prevented platelet
transfusions in a signiﬁcantly higher number of patients rela-
tive to placebo-treated patients [21,22]. In both studies,
patients had received chemotherapy with no dose reductions.
Platelet transfusions were given for platelet counts 20,000
cells/L or, if clinically indicated, for bleeding. Although
patients treated with rhIL-11 in the present study required
fewer transfusions on average than those treated with placebo,
the differences were not statistically signiﬁcant. These results
may have been due to factors unique to this study:
1) The study was designed to detect, with 80% power, a
mean reduction of at least five platelet transfusions for
either rhIL-11 group compared with placebo group. This
assumed that the SD for the total number of platelet trans-
fusions per patient was 5.6. However, the average SD was
7 or 25% higher than projected. This higher SD reduced
the power of the study from 80 to 58%, meaning that the
study had a 42% probability of yielding an inconclusive
result, even if treatment with rhIL-11 produced a mean
reduction of five platelet transfusions. Therefore, a larger
study may have yielded a more conclusive result.
2) There was an imbalance in the number of alloimmu-
nized patients randomized to rhIL-11 compared with the
placebo group. Of 13 patients already alloimmunized at
study entry, 12 were randomized to rhIL-11 and of the three
patients who became alloimmunized during the study, two
were in the rhIL-11 groups. Alloimmunized patients gener-
ally require more platelet transfusions than nonalloimmu-
nized patients and did so in this study. In addition, many of
our alloimmunized patients had delayed platelet engraft-
ment, likely from immune thrombocytopenia, and responded
to corticosteroids ( J.J.V., W.P.P., unpublished observations).
Data from the alloimmunized patients increased the mean
and SD of the number of platelet transfusions required by
each patient in the rhIL-11 groups. Because they require
more platelet transfusions, alloimmunized patients may ben-
efit most from an effective thrombopoietic agent. Future
studies should account for this factor in the randomization.
This study demonstrated that rhIL-11 can be adminis-
tered safely to patients with breast cancer after high-dose
chemotherapy with hematopoietic progenitor cell support.
The most signiﬁcant adverse events were edema, tachycar-
dia, hypotension, and conjunctival bleeding. rhIL-11 treat-
ment has been associated with dilutional anemia with an
increase in plasma volume possibly due to increased renal
sodium and water reabsorption [13]. In this trial, patients
were hydrated extensively during the phase of high-dose
chemotherapy and thereafter were given supplemental ﬂuid
with other supportive treatment (electrolytes, antibiotics,
antiemetics, and transfusions). Patients were transfused with
packed RBCs to maintain a hematocrit of at least 42%
(there was no difference in RBC transfusions among the
treatment groups). The resultant edema can theoretically
explain the low and statistically insignificant difference in
the incidence of transient atrial fibrillation in the placebo
and rhIL-11 groups. The use of diuretics was discouraged
because of the potential for renal insufficiency after high-
dose chemotherapy that included cisplatin. 
The numbers of patients with atrial arrhythmias, dysp-
nea, or congestive heart failure were similar and statistically
Table 5. Discontinuations due to adverse events
Treatment group
Patient number Event Relationa
Placebo
018 Myalgias Not related
047 Veno-occlusive liver disease Not related
058 Atrial flutter/fibrillation Possibly related
25 g/kg
005 Atrial tachycardia Possibly related
013 Veno-occlusive liver disease Possibly related
073 Atrial flutter/fibrillation Possibly related
50 g/kg
006 Atrial flutter/fibrillation Probably related
021 Alkaline phosphatase increased Unknown
023 Atrial flutter/fibrillation Possibly related
050 Ventricular pauseb Not related
083 Atrial flutter/fibrillation Possibly related
aAs reported by the investigator on the case report form.
bThis event occurred before the start of study drug and was captured on Holter
monitor.
The 11 patients who discontinued study drug because of an adverse event were
evenly distributed across treatment groups. 
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not different in the placebo and rhIL-11 groups. The inci-
dence of effects commonly associated with cytokines (e.g.,
fever, bone pain, myalgia) was similar for the placebo and
rhIL-11 groups.
There were no clinically or statistically signiﬁcant differ-
ences in times to neutrophil recovery among the groups, sug-
gesting that rhIL-11 does not add to the acceleration of neu-
trophil recovery stimulated by G-CSF in this setting. It would
also seem that rhIL-11 does not have any detrimental effect
on neutrophil recovery when given concomitantly with G-
CSF. This result is consistent with data on neutrophil recov-
ery in other randomized placebo-controlled studies [21,22].
The recovery of platelet reticulocytes was similar among
treatment groups, and platelet reticulocytes began increas-
ing several days before the recovery of platelet counts and
the achievement of platelet-transfusion independence. This
result is consistent with observations showing that an
increase in platelet reticulocytes is predictive of imminent
platelet recovery following myelosuppressive chemotherapy
and stem cell support.
Overall, the trend toward lower platelet transfusion
requirements in the rhIL-11 groups than in the placebo
group, the smaller SD of the number of platelet transfusions
given to patients in the rhIL-11 groups, and a lower per-
centage of patients with delayed platelet engraftment in the
rhIL groups despite the greater number of alloimmunized
patients in the rhIL-11 groups suggest that rhIL-11 may be
more effective in patients who are destined to have delayed
platelet recovery after high-dose chemotherapy with ABMT
and PBPC support than in those who are going to have rela-
tively rapid recovery without a thrombopoietic agent. This
promising possibility will require further study in patients
who have a risk of delayed recovery after ABMT or after
PBPC transplantation.
In conclusion, we have shown that rhIL-11 can be safely
administered at either 25 or 50 g/kg/day for up to 21 days
after high-dose chemotherapy with autologous hemato-
poietic progenitor cell support in patients with breast can-
cer. rhIL-11 resulted in a decrease in the number of platelet
transfusions required, but that difference was not statistical-
ly signiﬁcant. Future studies should stratify patients accord-
ing to whether they are or are not alloimmunized. Regimens
containing prolonged administration of IL-11 for more than
21 days should be evaluated for their effects on delayed
platelet engraftment after high-dose chemotherapy.
ACKNOWLEDGMENTS
We acknowledge Roxan Canales, RN, Judy Lawrence,
RN, the Bone Marrow Transplant Program’s unit nurses,
clinic nurses, and data management for their excellent ser-
vices, and Nancy Peret, RN, for her invaluable assistance in
monitoring this study.
REFERENCES
1 Hryniuk W, Bush H: The importance of dose intensity in chemo-
therapy of metastatic breast cancer. J Clin Oncol 2:1281, 1984.
2 Budman DR, Wood W, Henderson IC, Korzun A, Cooper R, Younger J,
Hart R, Moore A, Ellerton J, Norton L, Ferree C, Colangelo A, McIntyre O:
Initial findings of CALGB 8541: a dose and dose intensity trial of
cyclophosphamide (C), doxorubicin (A), and 5-ﬂuorouracil (F) as adju-
vant treatment of stage II, node 	, female breast cancer. Proc Am Soc
Clin Oncol 11:51, 1992. [abstr]
3 Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer
E, Kurtzberg J, Bast RC, Jones R, Shpall E, Wu K, Rosner G, Gilbert C,
Mathias B, Coniglio D, Petros W, Henderson C, Norton L, Weiss RB, Bud-
man D, Hurd D: High-dose chemotherapy and autologous bone mar-
row support as consolidation after standard-dose adjuvant therapy for
high-risk primary breast cancer. J Clin Oncol 11:1132, 1993.
4 Karolak L, Chandra A, Khan W, Marks B, Petros W, Peters W,
Greenberg C, Hannun Y: High-dose chemotherapy-induced platelet
defect: inhibition of platelet signal transduction pathways. Mol Phar-
macol 43:37, 1993.
5 Paul SR, Bennett F, Calvetti JA, Kelleher K, Wood CR, O’Hara Jr
RM, Leary AC, Sibley B, Clark SC, Williams DA, Yang Y-C: Molecular
cloning of a cDNA encoding interleukin 11, a stromal cell-derived lym-
phopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA
87:7512, 1990.
6 Yonemura Y, Kawakita M, Masuda T, Fujimoto K, Kato K, Takatsuki
K: Synergistic effects of interleukin 3 and interleukin 11 on murine
megakaryopoiesis in serum-free culture. Exp Hematol 20:1011, 1992.
7 Teramura M, Kobayashi S, Hoshino S, Oshimi K, Mizoguchi H: Inter-
leukin-11 enhances human megakaryocytopoiesis in vitro. Blood
79:327, 1992.
8 Bruno E, Briddell RA, Cooper RJ, Hoffman R: Effects of recombinant
interleukin 11 on human megakaryocyte progenitor cells. Exp Hematol
19:378, 1991.
9 Goldman SJ: Preclinical biology of interleukin 11: a multifunction-
al hematopoietic cytokine with potent thrombopoietic activity. Stem
Cells 13:462, 1995.
10 Champlin R, Mehra R, Kaye J, Woodin MB, Wood J, Andersson B, van
Besien K, Gajewski J, Przepiorka D, Deisseroth AB: Phase I study of
recombinant human interleukin-11 following autologous BMT in
patients with breast cancer. Proc Am Soc Clin Oncol 13:100, 1994.
[abstr]
11 Romp KG, Peters WP, Hoffman M: Reticulated platelet counts in
patients undergoing autologous bone marrow transplantation: an aid in
assessing marrow recovery. Am J Hematol 46:319, 1994.
12 Ault KA, Rinder HM, Mitchell J, Carmody MB, Vary CPH, Hillman
RS: The signiﬁcance of platelets with increased RNA content (reticulat-
ed platelets): a measure of the rate of thrombopoiesis. Am J Clin Pathol
98:637, 1992.
13 Ault KA, Mitchell J, Knowles C, Clendaniel A, Egan A, Loewy J, Gar-
nick MB, Kaye JA: Recombinant human interleukin eleven
(NEUMEGA™ rhIL-11 growth factor) increases plasma volume and
decreases urine sodium excretion in normal human subjects. Blood
84:276a, 1994. [abstr]
14 Dykstra K, Rogge H, Stone A, Loewy J, Schwertschlag U: Effect of
diuretic treatment on rhIL-11-induced salt and water retention. Blood
88 (Suppl. 1):346a, 1996. [abstr]
15 Gordon MS, Nemunaitis J, Hoffman R, Paquette RL, Rosenfeld C,
Manfreda S, Isaacs R, Nimer SD: A phase I trial of recombinant human
interleukin-6 in patients with myelodysplastic syndromes and thrombo-
cytopenia. Blood 85:3066, 1995.
16 Rintala E, Pulkki K, Mertsola J, Nevalainen T, Nikoskelainen J: Endo-
toxin, interleukin-6 and phospholipase-A2 as markers of sepsis in patients
with hematological malignancies. Scand J Infect Dis 27:39, 1995.
17 Dinarello CA: Biologic basis for interleukin-1 in disease. Blood
87:2095, 1996.
18 Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA:
High-dose recombinant interleukin 2 in the treatment of patients with
rhIL-11 in BMT for Breast Cancer
141B B & M T
disseminated cancer: responses, treatment-related morbidity, and histo-
logic ﬁndings. JAMA 256:3117, 1986.
19 Silgals RM, Ahlgren JD, Neefe JR, Rothman J, Rudnick S, Galicky P,
Schein PS: A phase II trial of high-dose intravenous interferon alpha-2
in advanced colorectal cancer. Cancer 54:2257, 1984.
20 Dutcher JP, Schiffer CA, Aisner J, Wiernik PH: Alloimmunization
following platelet transfusion: the absence of a dose-response relation-
ship. Blood 57:395, 1981.
21 Tepler I, Elias L, Smith II JW, Hussein M, Rosen G, Chang AY-C,
Moore JO, Gordon MS, Kuca B, Beach KJ, Loewy JW, Garnick MB, Kaye
JA: A randomized placebo-controlled trial of recombinant human
interleukin-11 in cancer patients with severe thrombocytopenia due to
chemotherapy. Blood 87:3607, 1996.
22 Isaacs C, Robert NJ, Bailey FA, Schuster MW, Overmoyer B, Graham M,
Cai B, Beach KJ, Loewy JW, Kaye JA: A randomized, placebo-controlled
study of recombinant human interleukin-11 to prevent chemotherapy-
induced thrombocytopenia in patients with breast cancer receiving dose-
intensive cyclophosphamide and doxorubicin. J Clin Oncol. In press.
JJ Vredenburgh et al.
142
